Stock listing
Frankfurt:4RD MaaT Pharma Aktie
German listing (Frankfurt) of MaaT Pharma · home listing Euronext:MAAT
Follow MaaT Pharma into a list and get an email when it puts out news.
Share price · FWB:4RD
€0.742 EUR -0.098 (-11.7%)
Close on Nov 20, 2026
- Day range
- €0.742 – €0.823 EURNov 20, 2026
- Market cap
- €13.96M EURAt the close on Nov 20, 2026 · price × 18.82M shares outstanding
- 52-week range
- €0.742 – €8.212 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €4,992 EURMedian day 0 shares · 41 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:MAAT · Home | €0.78 EUR | -0.12 (-13.3%) | 101,572 | €0.87 | €0.87 | €0.762 | €0.90 | Close on Nov 20, 2026 |
| Frankfurt:4RD | €0.742 EUR | -0.098 (-11.7%) | — | €0.823 | €0.823 | €0.742 | €0.840 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:4RD · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.069 | +0.065 | +6.5% | €0.944 | €1.089 | €0.941 | 0 | |
| €1.004 | +0.019 | +1.9% | €0.980 | €1.006 | €0.978 | 0 | |
| €0.985 | -0.006 | -0.6% | €0.988 | €0.996 | €0.985 | 11,940 | |
| €0.991 | -0.002 | -0.2% | €0.993 | €0.993 | €0.989 | 0 | |
| €0.993 | +0.001 | +0.1% | €0.991 | €0.994 | €0.978 | 0 | |
| €0.992 | -0.032 | -3.1% | €1.037 | €1.042 | €0.982 | 39,860 | |
| €1.024 | +0.022 | +2.2% | €1.012 | €1.025 | €1.011 | 18,166 | |
| €1.002 | -0.015 | -1.5% | €1.007 | €1.017 | €0.996 | 20,702 | |
| €1.017 | -0.005 | -0.5% | €1.026 | €1.026 | €1.008 | 0 | |
| €1.022 | -0.024 | -2.3% | €1.022 | €1.035 | €1.011 | 9,236 | |
| €1.046 | +0.021 | +2.0% | €1.038 | €1.057 | €1.036 | 5,520 | |
| €1.025 | -0.038 | -3.6% | €1.044 | €1.058 | €1.022 | 0 | |
| €1.063 | +0.021 | +2.0% | €1.015 | €1.121 | €1.014 | 0 | |
| €1.042 | +0.061 | +6.2% | €1.042 | €1.042 | €1.042 | 0 | |
| €0.981 | +0.022 | +2.3% | €0.957 | €0.985 | €0.956 | 0 | |
| €0.959 | +0.039 | +4.2% | €0.945 | €0.959 | €0.935 | 0 | |
| €0.920 | +0.035 | +4.0% | €0.908 | €0.928 | €0.907 | 0 | |
| €0.885 | +0.002 | +0.2% | €0.884 | €0.888 | €0.876 | 0 | |
| €0.883 | 0.000 | 0.0% | €0.880 | €0.889 | €0.877 | 0 | |
| €0.883 | -0.009 | -1.0% | €0.886 | €0.886 | €0.881 | 0 | |
| €0.892 | -0.028 | -3.0% | €0.893 | €0.895 | €0.890 | 12,710 | |
| €0.920 | -0.030 | -3.2% | €0.938 | €0.944 | €0.910 | 5,580 | |
| €0.950 | +0.009 | +1.0% | €0.953 | €0.955 | €0.949 | 0 | |
| €0.941 | +0.016 | +1.7% | €0.910 | €0.954 | €0.899 | 0 | |
| €0.925 | -0.076 | -7.6% | €0.965 | €0.971 | €0.913 | 300 | |
| €1.001 | -0.033 | -3.2% | €1.005 | €1.018 | €0.997 | 8,238 | |
| €1.034 | -0.080 | -7.2% | €1.012 | €1.036 | €1.006 | 0 | |
| €1.114 | -0.010 | -0.9% | €1.093 | €1.116 | €1.076 | 150 | |
| €1.124 | -0.063 | -5.3% | €1.115 | €1.127 | €1.109 | 0 | |
| €1.187 | -1.329 | -52.8% | €1.187 | €1.187 | €1.187 | 150 | |
| €2.516 | -0.008 | -0.3% | €2.516 | €2.516 | €2.516 | 0 | |
| €2.524 | -0.001 | 0.0% | €2.524 | €2.524 | €2.524 | 0 | |
| €2.525 | -0.001 | 0.0% | €2.525 | €2.525 | €2.525 | 0 | |
| €2.526 | -0.018 | -0.7% | €2.526 | €2.526 | €2.526 | 0 | |
| €2.544 | +0.008 | +0.3% | €2.544 | €2.544 | €2.544 | 0 | |
| €2.536 | +0.020 | +0.8% | €2.536 | €2.536 | €2.536 | 0 | |
| €2.516 | -0.018 | -0.7% | €2.516 | €2.516 | €2.516 | 0 | |
| €2.534 | +0.010 | +0.4% | €2.534 | €2.534 | €2.534 | 0 | |
| €2.524 | 0.000 | 0.0% | €2.524 | €2.524 | €2.524 | 0 | |
| €2.524 | -0.153 | -5.7% | €2.663 | €2.686 | €2.496 | 0 | |
| €2.677 | -0.103 | -3.7% | €2.769 | €2.801 | €2.658 | 6,368 | |
| €2.780 | +0.103 | +3.8% | €2.645 | €2.782 | €2.638 | 0 | |
| €2.677 | -0.122 | -4.4% | €2.725 | €2.731 | €2.669 | 0 | |
| €2.799 | -0.017 | -0.6% | €2.817 | €2.834 | €2.797 | 0 | |
| €2.816 | -0.118 | -4.0% | €2.878 | €2.878 | €2.801 | 0 | |
| €2.934 | +0.015 | +0.5% | €2.915 | €2.963 | €2.906 | 16,774 | |
| €2.919 | -0.017 | -0.6% | €2.874 | €2.941 | €2.831 | 0 | |
| €2.936 | -0.087 | -2.9% | €2.939 | €2.968 | €2.929 | 0 | |
| €3.023 | +0.115 | +4.0% | €2.937 | €3.033 | €2.922 | 0 | |
| €2.908 | -0.066 | -2.2% | €2.965 | €2.965 | €2.894 | 0 | |
| €2.974 | +0.014 | +0.5% | €2.979 | €2.987 | €2.964 | 20,640 | |
| €2.960 | -0.045 | -1.5% | €2.948 | €2.966 | €2.942 | 0 | |
| €3.005 | -0.020 | -0.7% | €3.020 | €3.032 | €2.987 | 0 | |
| €3.025 | -0.019 | -0.6% | €3.032 | €3.032 | €2.981 | 0 | |
| €3.044 | -0.075 | -2.4% | €3.124 | €3.131 | €3.021 | 0 | |
| €3.119 | -0.021 | -0.7% | €3.073 | €3.130 | €3.034 | 8,236 | |
| €3.140 | -0.023 | -0.7% | €3.139 | €3.183 | €3.133 | 0 |
- Ticker
- Frankfurt:4RD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
MaaT Pharma Reports Financial Results for the Third Quarter 2026
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 27 slides
Latest news
MaaT Pharma Provides an Update on Preliminary Findings from the Investigator-Sponsored Phase 2a PICASSO Trial in Metastatic Melanoma
Nov 6, 2026
Closed €1.07 (+6.5%) on Nov 6, 2026
MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors
Oct 19, 2026
Closed €1.04 (+6.2%) on Oct 20, 2026
MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update
Sep 29, 2026
Closed €1.11 (-0.9%) on Sep 30, 2026
MaaT Pharma publie ses résultats semestriels 2026 et fait le point sur ses activités
Sep 29, 2026
Closed €1.12 (-5.3%) on Sep 29, 2026
MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors
Sep 21, 2026
Closed €2.53 (-0.7%) on Sep 22, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Sep 18, 2026
Closed €2.54 (+0.8%) on Sep 18, 2026
MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe
Sep 15, 2026
Closed €2.52 (0.0%) on Sep 15, 2026
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract
Jul 6, 2026
Closed €2.67 (-2.3%) on Jul 7, 2026
MaaT Pharma on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 41 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 27 decks · latest October 2026
Where MaaT Pharma is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:MAAT · Home listing | Euronext | France | EUR |
| gettex:4RD | gettex | Germany | EUR |
| LS Exchange:A3C7A5 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3C7A5 | Lang & Schwarz | Germany | EUR |
| Frankfurt:4RD · This page | Frankfurt | Germany | EUR |
| OTC:MATPF | OTC | United States | USD |
| Hamburg:4RD | Hamburg | Germany | EUR |
| Munich:4RD | Munich | Germany | EUR |
| Stuttgart:4RD | Stuttgart | Germany | EUR |
| Dusseldorf:4RD | Dusseldorf | Germany | EUR |
Valuation
EV/sales 4.7× against a median of 2.7×: 3rd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €21.29M EUR
- P/E
- Loss
- EV/sales
- 4.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 30.7%
- Operating margin
- −754.9%
- Net margin
- −686.6%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Median of the others | US$16.24M | US$10.53M | 2.7× | −0.1× | 0.9× | −178.5% | 0.0× | 1.08 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.00 EUR · Analysts' mean
- EPS, year to Dec 2026
- -2.12 · 3 analysts
- Revenue, year to Dec 2026
- 5.78M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Hervé Affagard | CEO and co-founder |
| Eric Soyer | Chief Financial Officer |
| Guilhaume DEBROAS | MaaT Pharma – Investor Relations |
Board
| Director | Role |
|---|---|
| Jean-Marie Lefevre | Chairman of the Board – Non-Executive Director |
| Claude Bertrand | Independent director |
| Hervé Affagard | CEO and co-founder |
| Isabelle de Crémoux | Non-Executive Director |
| Jean Volatier | Independent director |
| Muriel Prudent | Non-Executive Director |
| Nadia Kamal | Independent director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Mar 30, 2026 | −16.0% |
| Quarter to Sep 30, 2025 | Nov 4, 2025 | −1.4% |
| Q2 2025 | Sep 17, 2025 | −4.7% |
| Quarter to Mar 31, 2025 | Apr 14, 2025 | +5.1% |
| Q4 2024 | Mar 27, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 5, 2024 | +1.9% |
| Q2 2024 | Sep 19, 2024 | +2.8% |
| Q1 2024 | Apr 2, 2024 · After close | +0.5% |
| Q4 2023 | Mar 28, 2024 | −5.0% |
| Q3 2023 | Nov 9, 2023 · After close | −2.4% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 27, 2023 · After close | −3.1% |
| Q1 2023 | May 9, 2023 · After close | −3.7% |
| Q4 2022 | Mar 30, 2023 | +3.1% |
| Q3 2022 | Nov 8, 2022 · After close | −1.1% |
| Q2 2022 | Jul 28, 2022 · After close | +1.0% |
| Q1 2022 | Apr 14, 2022 · Before open | 0.0% |
| Q3 2021 | Oct 20, 2021 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 28 slides | September 2026 |
| Investor Presentation (July 2026) | Investor deck | 28 slides | July 2026 |
| Shareholder Meeting (June 2026) | Shareholder meeting | 32 slides | Jun 16, 2026 |
| Investor Presentation (March 2026) | Investor deck | 28 slides | March 2026 |
| Investor Presentation (October 2025) | Investor deck | 31 slides | October 2025 |
| Investor Presentation (April 2025) | Investor deck | 32 slides | April 2025 |
| Investor Presentation (February 2025) | Investor deck | 32 slides | February 2025 |
| Investor Presentation (January 2025) | Investor deck | 33 slides | January 2025 |
| Technical Presentation (December 2024) | Technical | 25 slides | December 2024 |
All 27 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2024) | Investor deck | 22 slides | November 2024 |
| Investor Presentation (October 2024) | Investor deck | 34 slides | October 2024 |
| EBMT 2024 | Conference | 20 slides | October 2024 |
| Investor Presentation (May 2024) | Investor deck | 30 slides | May 2024 |
| Investor Presentation (April 2024) | Investor deck | 30 slides | April 2024 |
| Investor Presentation (March 2024) | Investor deck | 31 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 31 slides | January 2024 |
| Investor Presentation (December 2023) | Investor deck | 30 slides | December 2023 |
| Investor Presentation (September 2023) | Investor deck | 37 slides | September 2023 |
| Investor Presentation (July 2023) | Investor deck | 37 slides | July 2023 |
| Investor Presentation (June 2023) | Investor deck | 37 slides | June 2023 |
| Investor Presentation (January 2023) | Investor deck | 37 slides | January 2023 |
| Investor Presentation (August 2022) | Investor deck | 32 slides | August 2022 |
| Investor Day (June 2022) | Investor day | 93 slides | Jun 7, 2022 |
| Investor Presentation (May 2022) | Investor deck | 29 slides | May 6, 2022 |
| Investor Presentation (March 2022) | Investor deck | 29 slides | Mar 29, 2022 |
| Investor Presentation (January 2022) | Investor deck | 29 slides | Jan 23, 2022 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares Closed: €9.1M raised · €3.48 a share · Portzamparc, BNP Paribas Group Dealers: Portzamparc, BNP Paribas Group (lead) Buyers: PSIM represented by Bpifrance Investissement (pledged to subscribe for €1.5 million); Biocodex (€1.5 million); Fonds PSIM (Bpifrance Investissement) (€1.5 million); Invus Public Entities (€1.5 million) Insiders: Existing shareholders PSIM (Bpifrance Investissement) and Biocodex pledged to subscribe €1.5 million each, €3 million in total; Biocodex's president is a board member Use of proceeds: Fund its roadmap: preparing Xervyteg commercialization, MaaT033 development, FDA discussions, working capital and general corporate purposes | Nov 14, 2025 | US$10.58M |
| Loan with warrants attached Tranche closed: €3.5M raised · Warrants at €4.5898 for 240 months · Van Lanschot Kempen Dealers: Van Lanschot Kempen Buyers: European Investment Bank (EIB) (€37.5 million, 4-tranche loan with warrants attached); European Investment Bank (Tranche A loan of €3.5 million and 468,772 warrants) Use of proceeds: Advance late-stage hemato-oncology programs, including Xervyteg and MaaT033 | Nov 4, 2025 | US$4.02M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.52M | 3.22M | 2.23M | 1.43M | 972.0K | 0 | 89.3K | 892.0K | 109.3K |
| Cost of revenue | 3.13M | 1.25M | 1.44M | 339.0K | 166.0K | 164.0K | 97.0K | 79.0K | 3.50M |
| Gross profit | 1.39M | 1.97M | 784.0K | 1.09M | 806.0K | -164.0K | -7.70K | 813.0K | -3.39M |
| Research and development | 27.6M | 27.5M | 20.3M | 14.5M | 9.14M | 6.10M | 5.27M | 4.51M | |
| Selling, general and administrative | 8.22M | 2.66M | 2.35M | 1.47M | 1.17M | 1.29M | 922.0K | 787.0K | |
| Operating income | -34.1M | -28.4M | -19.9M | -13.6M | -8.89M | -7.39M | -4.96M | -4.40M | -4.71M |
| Depreciation and amortization | 1.74M | 1.69M | 871.0K | 429.0K | 328.0K | 164.0K | 97.0K | 79.0K | 51.2K |
| EBITDA | -32.4M | -26.7M | -19.1M | -13.1M | -8.56M | -7.22M | -4.87M | -4.33M | -4.66M |
| Interest expense | 1.27M | 868.0K | 413.0K | 201.0K | 121.0K | 45.0K | 20.0K | 71.0K | 0 |
| Income before tax | -34.9M | -32.4M | -19.7M | -13.7M | -9.02M | -6.79M | -5.84M | -4.47M | -4.78M |
| Income tax | -3.79M | -3.52M | -3.63M | 157.0K | 121.0K | -1.49M | 803.0K | 71.0K | -922.8K |
| Net income | -31.1M | -28.9M | -19.7M | -13.7M | -9.02M | -5.35M | -6.65M | -4.55M | -3.86M |
| Earnings per share, basic | -1.95 | -2.21 | -1.73 | -1.39 | -3.72 | -25.91 | -32.20 | -4.40 | -3.74 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 24.9M | 20.2M | 24.3M | 35.2M | 43.3M | 19.9M | 5.41M | 3.60M | 7.35M |
| Short-term investments | 95.0K | 66.0K | 34.0K | 63.0K | |||||
| Receivables | 6.82M | 1.51M | 5.16M | 1.05M | 3.51M | 2.24M | 1.50M | 794.0K | 4.23K |
| Inventory | 84.0K | 64.0K | 190.0K | 47.0K | 33.0K | -97.0K | 27.4K | 1 | 28.9K |
| Current assets | 33.0M | 27.6M | 32.0M | 42.1M | 47.3M | 22.2M | 6.98M | 4.73M | 8.79M |
| Property, plant and equipment | 7.33M | 8.60M | 9.17M | 966.0K | 1.11M | 1.10M | 428.0K | 391.0K | 313.0K |
| Goodwill | 44.1K | ||||||||
| Total assets | 44.6M | 38.5M | 42.9M | 44.7M | 49.4M | 24.3M | 8.17M | 5.88M | 9.26M |
| Accounts payable | 11.8M | 8.83M | 6.35M | 4.51M | 34.0K | 1.40M | 1.68M | 1.42M | 1.14M |
| Current liabilities | 17.0M | 14.6M | 11.5M | 9.22M | 4.70M | 2.86M | 2.63M | 2.24M | 1.45M |
| Long-term debt | 11.0M | 7.80M | 5.42M | 7.93M | 3.96M | 4.72M | 9.92M | 2.17M | |
| Total debt | 17.4M | 16.0M | 14.1M | 11.4M | 5.81M | 6.08M | 10.5M | 2.60M | 1.72M |
| Total liabilities | 42.8M | 28.2M | 22.5M | 17.9M | 9.56M | 8.34M | 12.7M | 4.62M | 3.99M |
| Shareholders' equity | 1.80M | 10.3M | 20.5M | 26.8M | 39.9M | 15.9M | -4.57M | 1.27M | 5.27M |
| Shares outstanding | 15.9M | 13.1M | 11.4M | 9.89M | 2.43M | 206.5K | 206.5K | 1.03M | 1.03M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.9M | -22.0M | -18.7M | -12.6M | -7.93M | -5.81M | -5.02M | -3.87M | -3.87M |
| Capital spending | -609.0K | -753.0K | -1.09M | -662.0K | -238.0K | -316.0K | -128.0K | -291.0K | -291.0K |
| Free cash flow | -16.5M | -22.8M | -19.8M | -13.3M | -8.17M | -6.13M | -5.15M | -4.16M | -4.16M |
| Cash from investing | -497.0K | -416.0K | -440.0K | -815.0K | -238.0K | -523.0K | -154.0K | -311.0K | -311.0K |
| Cash from financing | 21.1M | 18.3M | 8.14M | 5.36M | 31.6M | 20.8M | 6.98M | 432.0K | 432.0K |
| Share buybacks | -45.0K | 17.3M | -79.0K | -137.0K | 32.4M | 18.0M | 0 | 28.0K | |
| Change in cash | 4.71M | -4.13M | -11.0M | -8.06M | 23.4M | 14.5M | 1.81M | -3.75M | -3.75M |
Cap table
Built by 6ix from MaaT Pharma’s releases · as of Nov 14, 2025
- Common shares
- 18,824,425
- Fully diluted
- 18,824,425
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 18,824,425 |
Warrants and options
| Lot |
|---|
| Warrants · €4.59 · expire about Nov 2045 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 18,824,425 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Claude Bertrand | Independent director · Since at least Jun 24, 2025 |
| Eric Soyer | Chief Financial Officer · Since at least Oct 19, 2026 |
| Guilhaume DEBROAS | MaaT Pharma – Investor Relations · Since at least Dec 8, 2025 |
| Hervé Affagard | CEO and co-founder · Since at least Oct 19, 2026 |
| Isabelle de Crémoux | Non-Executive Director · Since at least Nov 5, 2026 |
| Jean-Marie Lefevre | Chairman of the Board – Non-Executive Director · Since at least Jun 24, 2025 |
| Jean Volatier | Independent director · Since at least Jun 24, 2025 |
| Muriel Prudent | Non-Executive Director · Since at least Nov 5, 2026 |
| Nadia Kamal | Independent director · Since at least Jun 24, 2025 |
Log in to ask 6ix AI your own questions about MaaT Pharma.